Market Cap 858.55M
Revenue (ttm) 203.07M
Net Income (ttm) -54.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -27.01%
Debt to Equity Ratio -6.54
Volume 10,175,200
Avg Vol 2,277,226
Day's Range N/A - N/A
Shares Out 156.39M
Stochastic %K 78%
Beta 0.65
Analysts Strong Sell
Price Target $6.30

Company Profile

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 445 5704
Address:
1375 West Fulton Street, Suite 1300, Chicago, United States
BuyThisOne
BuyThisOne Aug. 8 at 1:38 PM
$XERS @soxboys21 where you at with all the goodies bro?
0 · Reply
RunningRobert1
RunningRobert1 Aug. 8 at 1:37 PM
$XERS Did Xeris Just Have Their Best Quarter Ever? https://youtu.be/EAEetUN2168 They did, and it puts them into a good position, if they can keep growing sales they should have enough cash to fund the XP trial without issue!
0 · Reply
Gety
Gety Aug. 8 at 1:23 PM
$XERS the price target is raised to 11 by some analyst. Don't know which one though. Any other raise?
1 · Reply
StarF
StarF Aug. 8 at 1:21 PM
$XERS low volume in pree market...
0 · Reply
Alon_R
Alon_R Aug. 8 at 1:19 PM
$XERS Just look at this cake... And take into account, that Recorlev just fulfilled by now, ~10-15% of it growth expectancy... it just has started! That's about it.
1 · Reply
RM03
RM03 Aug. 8 at 1:17 PM
$XERS - would be great to see another high volume (short covering) day with a 0.20 move up!
0 · Reply
Northwoodspeculator
Northwoodspeculator Aug. 8 at 1:10 PM
$XERS resistance may diminish over 10 once shorts cover their positions. Then a little news and some institutional buying , maybe some sector rotation. Who knows ? I think I will stay the course and hold for a year.
0 · Reply
DixonCider
DixonCider Aug. 8 at 1:06 PM
$CAPR Monday morning Type A meeting. To accommodate this meeting, the Company has rescheduled the release of its financial results for the second quarter ended June 30, 2025, to Monday, August 11, 2025, after the market close. Management will host a webcast and conference call at 4:30 p.m. ET on the same day to review the financial results and provide a corporate update “Same day” $XERS my largest holding could catch my second largest holding SP 😱
3 · Reply
Bullisch_150
Bullisch_150 Aug. 8 at 11:32 AM
$XERS wowwww powerstock!! we fly to 20$ next 2 months minimum
1 · Reply
therealpoub
therealpoub Aug. 8 at 11:20 AM
$XERS Paul crushed it yesterday. Up a cool mil.
1 · Reply
Latest News on XERS
Xeris Announces Details for Analyst & Investor Day

May 20, 2025, 7:30 AM EDT - 2 months ago

Xeris Announces Details for Analyst & Investor Day


Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings

May 7, 2025, 11:51 AM EDT - 3 months ago

Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings


Xeris Announces Changes to Its Board of Directors

Mar 28, 2025, 8:00 AM EDT - 4 months ago

Xeris Announces Changes to Its Board of Directors


Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

Feb 24, 2025, 8:00 AM EST - 5 months ago

Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer


Xeris to Participate in Upcoming Investor Conferences

Feb 5, 2025, 8:00 AM EST - 6 months ago

Xeris to Participate in Upcoming Investor Conferences


Xeris Expects to Exceed Full-Year 2024 Financial Guidance

Jan 10, 2025, 7:00 AM EST - 7 months ago

Xeris Expects to Exceed Full-Year 2024 Financial Guidance


Xeris Biopharma Reports Third Quarter 2024 Financial Results

Nov 8, 2024, 7:00 AM EST - 9 months ago

Xeris Biopharma Reports Third Quarter 2024 Financial Results


Xeris Biopharma: Time For A Reassessment

Oct 9, 2024, 11:33 AM EDT - 10 months ago

Xeris Biopharma: Time For A Reassessment


Xeris Biopharma Announces CEO Succession Plan

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Xeris Biopharma Announces CEO Succession Plan


Xeris Biopharma: Checking-In On One Of My 'Top Ideas'

Mar 30, 2024, 1:28 AM EDT - 1 year ago

Xeris Biopharma: Checking-In On One Of My 'Top Ideas'


Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 12:43 PM EST - 1 year ago

Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript


Xeris Biopharma Updates Its Outlook for 2023

Jan 4, 2024, 7:00 AM EST - 1 year ago

Xeris Biopharma Updates Its Outlook for 2023


BuyThisOne
BuyThisOne Aug. 8 at 1:38 PM
$XERS @soxboys21 where you at with all the goodies bro?
0 · Reply
RunningRobert1
RunningRobert1 Aug. 8 at 1:37 PM
$XERS Did Xeris Just Have Their Best Quarter Ever? https://youtu.be/EAEetUN2168 They did, and it puts them into a good position, if they can keep growing sales they should have enough cash to fund the XP trial without issue!
0 · Reply
Gety
Gety Aug. 8 at 1:23 PM
$XERS the price target is raised to 11 by some analyst. Don't know which one though. Any other raise?
1 · Reply
StarF
StarF Aug. 8 at 1:21 PM
$XERS low volume in pree market...
0 · Reply
Alon_R
Alon_R Aug. 8 at 1:19 PM
$XERS Just look at this cake... And take into account, that Recorlev just fulfilled by now, ~10-15% of it growth expectancy... it just has started! That's about it.
1 · Reply
RM03
RM03 Aug. 8 at 1:17 PM
$XERS - would be great to see another high volume (short covering) day with a 0.20 move up!
0 · Reply
Northwoodspeculator
Northwoodspeculator Aug. 8 at 1:10 PM
$XERS resistance may diminish over 10 once shorts cover their positions. Then a little news and some institutional buying , maybe some sector rotation. Who knows ? I think I will stay the course and hold for a year.
0 · Reply
DixonCider
DixonCider Aug. 8 at 1:06 PM
$CAPR Monday morning Type A meeting. To accommodate this meeting, the Company has rescheduled the release of its financial results for the second quarter ended June 30, 2025, to Monday, August 11, 2025, after the market close. Management will host a webcast and conference call at 4:30 p.m. ET on the same day to review the financial results and provide a corporate update “Same day” $XERS my largest holding could catch my second largest holding SP 😱
3 · Reply
Bullisch_150
Bullisch_150 Aug. 8 at 11:32 AM
$XERS wowwww powerstock!! we fly to 20$ next 2 months minimum
1 · Reply
therealpoub
therealpoub Aug. 8 at 11:20 AM
$XERS Paul crushed it yesterday. Up a cool mil.
1 · Reply
BuyThisOne
BuyThisOne Aug. 8 at 10:11 AM
$XERS They paid off $12 million of debt last quarter and cash still went up half a million!
4 · Reply
Bullisch_150
Bullisch_150 Aug. 8 at 9:26 AM
$XERS We're going to stay on course; this will be a huge biotech. Four products will be on the market soon. And deals with major pharmaceutical companies in early stages. This company is the best long-term investment. A major buyout offer may be coming soon. Why invest in this company? * The three products will generate increasingly higher revenues. * Product 4 will be released in Q3. * Buyout is possible at any time. A deal will be made for 8121 for phase 3, which will provide them with a significant milestone payment and a share of the revenue.
1 · Reply
Alon_R
Alon_R Aug. 8 at 9:16 AM
$XERS So what caused Adma, decent company, grossing ~50%, 240M shares outstanding, with asset which is incomparable to Xeris asset(as i see it and as it folding out lately), to jump from 5-6$ zone to 23$ during 8 months? They were able to improve quarterly around 3-4 cents p/s, 4 Q's sequentially(it's a lot). For that very reason they found themselves with +0.13$ eps/Q and 23$ on the very same year they've been traded for 5$ So why they've faltered since? Rev. growth is insufficient as it was 2024,for a company grossing just over 50%,with 240M S.O I think people not yet fully acknowledged the strength of Xeris Assets(esp. Recorlev). Xeris absolutely may jump now within a year to 20-30$, based on strong growth. But major difference between Xeris to Adma,is that Xeris has legs to keep on growing fast all the way to 2030. I always say ~70$ expectancy 2029-30. But it could be 120$,just as it could be 50$ based on growth fulfillment, with XP-8121 as a very luring forward looking ahead.
1 · Reply
Bullisch_150
Bullisch_150 Aug. 8 at 3:46 AM
$XERS Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid PDF Version First concentrated, ready-to-dilute liquid glucagon available for growing procedural gastroenterology market American Regent to commercialize GVOKE VialDx™ Availability is expected in the third quarter of 2025
2 · Reply
Bullisch_150
Bullisch_150 Aug. 8 at 3:42 AM
$XERS Product 4 for sale is also arriving immediately!!! Crazy stock!
1 · Reply
BuyThisOne
BuyThisOne Aug. 8 at 12:14 AM
$XERS I am always collecting different screen shots on my journey here. Our first billion with many more to come. The first billion took 7 years. I think the next will take about a year from here or so.
1 · Reply
BuyThisOne
BuyThisOne Aug. 7 at 11:55 PM
$XERS Path forward might look something like this. Like any analyst we are all just making educated guesses. I like to think I have done pretty well with my guesses and my accounts would agree. This does not even account for levo approval expected in 2030.
1 · Reply
BuyThisOne
BuyThisOne Aug. 7 at 11:29 PM
$XERS For those of us that know, it should not be understated the impact you have had on sharing due diligence on this stock. Your efforts helped me get to my first 100k shares. Now sitting at 308k shares here I have to thank you and the other level headed people here that always provided clear facts and analysis. This is a totally different company than it was in 2020. Some things didn't pan out but other things are now home runs and making up for it. As I have always said, this will be an interesting journey like watching a child grow. I for one hope I get the chance to watch this thing grow for at least another 10 years. Today was just a very small preview of what's to come. The house that Paul built, don't forget it. Thanks Chris and the other true believers here. We did our best to convince others what this company was. You can lead a horse to water as they say. Congrats, we all deserve this the most.
1 · Reply
topdownagain
topdownagain Aug. 7 at 11:24 PM
$XERS compared to the all-time chart, there's room for improvement as far the upside goes:
0 · Reply
TheCatInTheHat1
TheCatInTheHat1 Aug. 7 at 11:21 PM
$XERS Peaple talking about 5+ years. Been here for over 5. I want my payday now and will get it.
1 · Reply
hashemtrade
hashemtrade Aug. 7 at 9:50 PM
$XERS This baby is preparing this year for the $35+ party 2027
1 · Reply
Flipperthedolphin
Flipperthedolphin Aug. 7 at 9:34 PM
$SGMO $XERS XERS pre market price +24%+ Closing price +20%+ Dinner time price :call it +18% from prior close ✅ SGMO Premarket price -3% Closing price -9% Dinner time price call it -17% from prior close ❌
0 · Reply